Antares Pharma
Market Cap
US$711.7m
Last Updated
2021/03/03 23:56 UTC
Data Sources
Company Financials +
Executive Summary
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Undervalued with excellent balance sheet.
Similar Companies
Share Price & News
How has Antares Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ATRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ATRS's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
-4.7%
ATRS
-3.1%
US Medical Equipment
-3.4%
US Market
1 Year Return
26.3%
ATRS
28.0%
US Medical Equipment
29.4%
US Market
Return vs Industry: ATRS underperformed the US Medical Equipment industry which returned 28% over the past year.
Return vs Market: ATRS underperformed the US Market which returned 29.4% over the past year.
Shareholder returns
| ATRS | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.7% | -3.1% | -3.4% |
| 30 Day | -1.6% | -1.5% | 0.6% |
| 90 Day | 31.0% | 5.0% | 6.3% |
| 1 Year | 26.3%26.3% | 29.0%28.0% | 32.2%29.4% |
| 3 Year | 72.2%72.2% | 69.2%65.1% | 51.3%41.7% |
| 5 Year | 374.4%374.4% | 151.7%133.8% | 119.6%95.2% |
Long-Term Price Volatility Vs. Market
How volatile is Antares Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Imagine Holding Antares Pharma (NASDAQ:ATRS) Shares While The Price Zoomed 347% Higher2 weeks ago | Simply Wall St
We Think Antares Pharma (NASDAQ:ATRS) Can Stay On Top Of Its Debt1 month ago | Simply Wall St
What Is The Ownership Structure Like For Antares Pharma, Inc. (NASDAQ:ATRS)?Valuation
Is Antares Pharma undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ATRS ($4.27) is trading below our estimate of fair value ($11.99)
Significantly Below Fair Value: ATRS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ATRS is good value based on its PE Ratio (12.6x) compared to the US Medical Equipment industry average (51.7x).
PE vs Market: ATRS is good value based on its PE Ratio (12.6x) compared to the US market (21.4x).
Price to Earnings Growth Ratio
PEG Ratio: ATRS is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: ATRS is overvalued based on its PB Ratio (6x) compared to the US Medical Equipment industry average (5.2x).
Next Steps
Future Growth
How is Antares Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
13.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATRS's forecast earnings growth (13.3% per year) is above the savings rate (2%).
Earnings vs Market: ATRS's earnings (13.3% per year) are forecast to grow slower than the US market (19.6% per year).
High Growth Earnings: ATRS's earnings are forecast to grow, but not significantly.
Revenue vs Market: ATRS's revenue (14% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: ATRS's revenue (14% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATRS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Antares Pharma performed over the past 5 years?
59.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATRS has a high level of non-cash earnings.
Growing Profit Margin: ATRS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ATRS has become profitable over the past 5 years, growing earnings by 59.6% per year.
Accelerating Growth: ATRS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ATRS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.8%).
Return on Equity
High ROE: ATRS's Return on Equity (47.2%) is considered outstanding.
Next Steps
Financial Health
How is Antares Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ATRS's short term assets ($126.6M) exceed its short term liabilities ($63.2M).
Long Term Liabilities: ATRS's short term assets ($126.6M) exceed its long term liabilities ($30.2M).
Debt to Equity History and Analysis
Debt Level: ATRS's debt to equity ratio (34.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ATRS's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ATRS's debt is well covered by operating cash flow (52.1%).
Interest Coverage: ATRS's interest payments on its debt are well covered by EBIT (3.6x coverage).
Balance Sheet
Next Steps
Dividend
What is Antares Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.4yrs
Average management tenure
CEO
Bob Apple (54 yo)
5.17yrs
Tenure
US$3,514,955
Compensation
Mr. Robert F. Apple, also known as Bob, has been the Chief Executive Officer and President of Antares Pharma Inc. since January 25, 2016. Mr. Apple served as Chief Operating Officer of Antares Pharma Inc. ...
CEO Compensation Analysis
Compensation vs Market: Bob's total compensation ($USD3.51M) is above average for companies of similar size in the US market ($USD2.20M).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.17yrs | US$3.51m | 0.91% $ 6.5m | |
| Executive VP & CFO | 4.42yrs | US$1.39m | 0.28% $ 2.0m | |
| Executive VP of Human Resources | 5.67yrs | US$1.36m | 0.19% $ 1.4m | |
| Senior Vice President of Operations | no data | no data | no data | |
| Principal Accounting Officer | 4.5yrs | US$361.46k | no data | |
| Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior Vice President of Corporate Business Development | 1.25yrs | no data | no data | |
| Senior Vice President of Technology Portfolio & Intellectual Property | no data | US$467.99k | no data | |
| Interim EVP | 0.92yr | no data | no data | |
| Senior Vice President of Device Business & Alliances | 1.17yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 5yrs | no data | no data | |
| Senior Vice President of Product Development | 4.17yrs | no data | no data |
4.4yrs
Average Tenure
58yo
Average Age
Experienced Management: ATRS's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.17yrs | US$3.51m | 0.91% $ 6.5m | |
| Independent Director | 7.67yrs | US$197.00k | 0.053% $ 376.5k | |
| Independent Chairman | 12.42yrs | US$327.50k | 0.13% $ 908.4k | |
| Independent Director | 17.42yrs | US$217.75k | 0.12% $ 829.2k | |
| Independent Director | 17.42yrs | US$221.75k | 0.23% $ 1.6m | |
| Independent Director | 2.25yrs | US$185.00k | 0% $ 0 | |
| Independent Director | 2yrs | US$223.40k | 0% $ 0 |
7.7yrs
Average Tenure
63yo
Average Age
Experienced Board: ATRS's board of directors are considered experienced (7.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Top Shareholders
Company Information
Antares Pharma, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Antares Pharma, Inc.
- Ticker: ATRS
- Exchange: NasdaqCM
- Founded: 1978
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$711.691m
- Shares outstanding: 166.67m
- Website: https://www.antarespharma.com
Number of Employees
Location
- Antares Pharma, Inc.
- 100 Princeton South
- Suite 300
- Ewing
- New Jersey
- 8628
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ATRS | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Feb 2001 |
| MJC | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2001 |
Biography
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company’s injecti...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/03 23:56 |
| End of Day Share Price | 2021/03/03 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.